Back HIV Treatment Experimental HIV Drugs

Experimental HIV Drugs

Janssen and ViiV to Develop NRTI-free Single-tablet Regimen

Janssen R&D and ViiV Healthcare announced last week that they will collaborate on the development of a dual single-tablet regimen containing the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine and the new integrase inhibitor dolutegravir, to be used as maintenance therapy for people who achieve viral suppression using a traditional regimen.

alt

Read more:

CROI 2014: New NNRTI Doravirine Matches Efavirenz for First-line HIV Treatment

The next-generation non-nucleoside reverse transcriptase inhibitor doravirine (formerly MK-1439) showed potent antiretroviral activity and good tolerability in combination with tenofovir/emtricitabine (the drugs in Truvada) in a dose-finding study presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

Read more:

CROI 2014: Long-Acting HIV Drugs for Maintenance Therapy [VIDEO]

A combination of 2 antiretrovirals used as maintenance therapy for people with undetectable viral load -- the next-generation integrase inhibitor GSK1265744 and the NNRTI rilpivirine (Edurant) -- led to continued viral suppression in more than 80% of treated patients, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

This study was done in preparation for a trial of long-acting injectable formulations of GSK1265744 (or GSK744 for short) and rilpivirine. These findings suggest that these drugs may be feasible for long-term maintenance therapy, though concerns remain about development of resistance under certain circumstances.

[David Margolis, CROI press conference, March 5, 2014]

See also: CROI 2014: Novel 2-Drug Maintenance Combo Works Well, Stage Set for Long-lasting Injectable [study report]

3/10/14

Reference

D Margolis, C Brinson, J Eron, et al. 744 and Rilpivirine as Two-Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 91LB.

CROI 2014: Novel 2-Drug Maintenance Combo Works Well, Stage Set for Long-lasting Injectables

An oral combination of 2 antiretroviral drugs -- the non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant, also in Complera or Eviplera) and the new integrase inhibitor GSK1265744 -- was at least as effective as a standard NRTIs-plus-efavirenz triple combination in keeping viral load undetectable, according to a report presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

Read more:

CROI 2014: Raltegravir Works as Well as Tenofovir for HIV Treatment [VIDEO]

A NRTI-sparing first-line antiretroviral regimen of raltegravir (Isentress) plus ritonavir-boosted darunavir (Prezista) worked as well as standard therapy containing tenofovir/emtricitabine (the drugs in Truvada), according to results from the NEAT 001 trial presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

[Francois Raffi, CROI press conference, March 5, 2014]

See also: CROI 2014: Raltegravir Plus Boosted Darunavir Is Safe and Effective for First-line ART [study report]

3/10/14

Reference

F Raffi, AG Babiker, L Richert, et al. First-Line RAL + DRV/r Is Non-Inferior To TDF/FTC + DRV/r: The NEAT001/ANRS143 Randomised Trial. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 84LB.